{"nctId":"NCT00880620","briefTitle":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","startDateStruct":{"date":"2009-04"},"conditions":["Parkinson's Disease"],"count":381,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"IPX066 145 mg LD","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: IPX066 95 mg LD","Drug: IPX066 145 mg LD"]},{"label":"IPX066 245 mg LD","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: IPX066 95 mg LD","Drug: IPX066 145 mg LD","Drug: IPX066 195 mg LD","Drug: IPX066 245 mg LD"]},{"label":"IPX066 390 mg LD","type":"EXPERIMENTAL","interventionNames":["Drug: IPX066 95 mg LD","Drug: IPX066 145 mg LD","Drug: IPX066 195 mg LD","Drug: IPX066 245 mg LD"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"IPX066 95 mg LD","otherNames":["CD-LD ER 95 mg"]},{"name":"IPX066 145 mg LD","otherNames":["CD-LD ER 145 mg"]},{"name":"IPX066 195 mg LD","otherNames":["CD-LD ER 195 mg"]},{"name":"IPX066 245 mg LD","otherNames":["CD-LD ER 245 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Able to understand and willing to voluntarily sign an informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization or local equivalent if applicable.\n2. Diagnosed with idiopathic PD.\n3. LD-na√Øve: defined as subjects not exposed to LD or catechol-O-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.\n4. If currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type B (MAO-B) inhibitor, maintains a stable regimen for at least 4 weeks prior to Baseline, and agrees to maintain the stable regimen throughout study participation.\n5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.\n6. Able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Diagnosed with atypical Parkinsonism or any known secondary parkinsonian syndrome.\n3. Prior functional neurosurgical treatment for PD or if such procedures are anticipated during study participation.\n4. Use of nonselective MAO inhibitors.\n5. Use of dopamine agonists within 30 days prior to Screening.\n6. Unable to tolerate a placebo regimen, in the Investigator's opinion.\n7. Treatment of psychosis with any antipsychotic.\n8. History of seizure or epilepsy.\n9. Active or prior medical condition or prior surgical procedure that would interfere with LD absorption.\n10. History of narrow-angle glaucoma.\n11. Subjects with a history of malignant melanoma.\n12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.\n13. Received any investigational medications during the 30 days prior to Screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30","description":"Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at Week 30 (End of Study).\n\nUnified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome.\n\nSubscales II and III were summed:\n\nPart I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"10.37"},{"groupId":"OG001","value":"-11.7","spread":"10.97"},{"groupId":"OG002","value":"-12.9","spread":"11.42"},{"groupId":"OG003","value":"-14.9","spread":"11.85"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline to End of Study in Mean Parkinson's Disease Questionnaire-39 (PDQ-39) Score","description":"Change from Baseline in Parkinson's disease Questionnaire 39 (PDQ-39) at Weeks 4, 9, 16, 23 and 30 or early discontinuation was collected. The PDQ-39 is a self-reported questionnaire consisting of 39 questions regarding the subjects mobility and the responses consist of \"Never\" (better in outcome), (value 0), \"Occasionally\" (value 1), \"Sometimes\" (value 2), , \"Often\" (value 3), and \"Always\" (value 4), (worse in outcome). The minimum possible score is \"0\" and the maximum is \"156\". The outcome measure calculated was the change from baseline to end of study in mean PDQ-39 score. Negative values indicate a better result.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"12.18"},{"groupId":"OG001","value":"-3.8","spread":"12.16"},{"groupId":"OG002","value":"-6.0","spread":"12.30"},{"groupId":"OG003","value":"0.6","spread":"11.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":92},"commonTop":["Nausea","Headache","Dizziness","Insomnia","Abnormal dreams"]}}}